AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

Discover how CobbleStone Software provides Upstate Medical University with a solution to their contract management needs by utilizing CobbleStone Contract Insight®. "Healthcare organizations can ...

Currently approved IL-5 monoclonal antibodies include mepolizumab (Nucala) and benralizumab (Fasenra), with dosing every 4 and 8 weeks, respectively. "Adherence to biologics is actually poorly ...

Fasenra (benralizumab) is a brand-name subcutaneous injection that’s prescribed for severe eosinophilic asthma in certain people. Fasenra hasn’t been reported to interact with alcohol ...

The Xanthine Dehydrogenase/Oxidase pipeline drugs market research report outlays comprehensive information on the Xanthine Dehydrogenase/Oxidase targeted therapeutics, complete with analysis by ...